[1]马洪俊,王玉平,刘 毅.替米沙坦不同给药时间对高血压患者血压监测参数及超敏C反应蛋白的影响[J].医学信息,2022,35(14):99-101.[doi:10.3969/j.issn.1006-1959.2022.14.023]
 MA Hong-jun,WANG Yu-ping,LIU Yi.Effects of Different Administration Time of Telmisartan on Blood Pressure Monitoring Parameters and High-sensitivity C-reactive Protein in Patients with Hypertension[J].Medical Information,2022,35(14):99-101.[doi:10.3969/j.issn.1006-1959.2022.14.023]
点击复制

替米沙坦不同给药时间对高血压患者血压监测参数及超敏C反应蛋白的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年14期
页码:
99-101
栏目:
论著
出版日期:
2022-07-15

文章信息/Info

Title:
Effects of Different Administration Time of Telmisartan on Blood Pressure Monitoring Parameters and High-sensitivity C-reactive Protein in Patients with Hypertension
文章编号:
1006-1959(2022)14-0099-03
作者:
马洪俊王玉平刘 毅
(天津市滨海新区海滨人民医院心脏内科,天津 300280)
Author(s):
MA Hong-junWANG Yu-pingLIU Yi
(Department of Cardiology,Haibin People’s Hospital,Binhai New Area,Tianjin 300280,China)
关键词:
高血压替米沙坦动态血压监测超敏C反应蛋白给药时间
Keywords:
HypertensionTelmisartanAmbulatory blood pressure monitoringHigh-sensitivity C-reactive proteinAdministration time
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2022.14.023
文献标志码:
A
摘要:
目的 探讨替米沙坦不同给药时间对高血压患者血压监测参数及超敏C反应蛋白(hs-CRP)的影响。方法 选取2019年8月-2020年8月天津市滨海新区海滨人民医院心脏内科收治的112例高血压患者,按照随机数字表法分为对照组与观察组,各56例。两组患者均采用替米沙坦治疗,对照组于清晨给药,观察组于夜间给药,比较两组动态血压监测参数、晨峰血压、夜间血压下降百分率(PER)、血压类型分布、hs-CRP、动脉硬化指数(AASI)及不良反应。结果 两组治疗后动态血压监测参数均低于治疗前,且观察组夜间平均收缩压(nSBP)、夜间平均舒张压(nDBP)均低于对照组(P<0.05);观察组治疗后晨峰血压低于对照组,PER高于对照组(P<0.05);两组治疗后杓型高血压患者占比增加,非杓型高血压患者占比减少,且观察组杓型高血压患者占比高于对照组,非杓型高血压占比低于对照组(P<0.05);两组治疗后hs-CRP、AASI均低于治疗前,且观察组低于对照组(P<0.05)。结论 替米沙坦夜间给药可降低高血压患者的夜间血压水平,恢复血压昼夜节律,纠正血压异常类型,同时降低hs-CRP及AASI指标,其效果优于早间服药。
Abstract:
Objective To investigate the effects of different administration times of telmisartan on blood pressure monitoring parameters and high-sensitivity C-reactive protein (hs-CRP) in patients with hypertension.Methods A total of 112 hypertensive patients who were admitted to the Department of Cardiology, Haibin People’s Hospital of Tianjin Binhai New Area from August 2019 to August 2020 were selected and divided into a control group and an observation group according to a random number table, with 56 cases in each group. Both groups of patients were treated with telmisartan. The control group was administered in the morning and the observation group was administered at night. The ambulatory blood pressure monitoring parameters, morning peak blood pressure, nocturnal blood pressure drop percentage (PER), blood pressure type distribution, hs-CRP, arteriosclerosis index (AASI) and adverse reactions were compared between the two groups.Results The ambulatory blood pressure monitoring parameters of the two groups after treatment were lower than those before treatment, and the nocturnal mean systolic blood pressure (nSBP) and nocturnal mean diastolic blood pressure (nDBP) of the observation group were lower than those of the control group (P<0.05). The morning peak blood pressure in the observation group was lower than that in the control group, and PER was higher than that in the control group(P<0.05). After treatment, the proportion of patients with dipper hypertension increased and the proportion of patients with non-dipper hypertension decreased in the two groups, and the proportion of patients with dipper hypertension in the observation group was higher than that in the control group, while the proportion of patients with non-dipper hypertension was lower than that in the control group(P<0.05). After treatment, hs-CRP and AASI in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group(P<0.05).Conclusion Night-time administration of telmisartan can reduce the nocturnal blood pressure level of patients with hypertension, restore the circadian rhythm of blood pressure, correct the type of abnormal blood pressure, and reduce hs-CRP and AASI indexes. The effect is better than that of early medication.

参考文献/References:

[1]孟庆平,张亚丽.替米沙坦与氯沙坦治疗原发性高血压的疗效对比[J].现代诊断与治疗,2021,32(12):1886-1888.[2]刘樟寿.拉西地平联合替米沙坦治疗原发性高血压的效果观察及安全性评价[J].心血管病防治知识,2020,10(35):15-18.[3]李韶华.替米沙坦不同给药时间治疗高血压的效果比较[J].临床合理用药杂志,2021,14(16):41-43.[4]张莉,庄梅.替米沙坦不同服药时间对非杓型伴清晨高血压患者疗效的对比研究[J].中华老年心脑血管病杂志,2018,20(4):385-388.[5]杨春芳.左旋氨氯地平联合厄贝沙坦不同时间服药纠正非杓型老年高血压的时辰药理学比较[J].临床合理用药杂志,2020,13(14):40-41.[6]杨英君,刘圣林,廖苑君,等.社区老年高血压患者用药时间对血压控制及预后影响[J].社区医学杂志,2020,18(9):668-671.[7]高血压联盟(中国),中国医疗保健国际交流促进会高血压分会,中国高血压防治指南修订委员会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.[8]于洋.替米沙坦不同给药时间治疗高血压的疗效分析研究[J].中国处方药,2019,17(9):93-94.[9]Zhang J,Sun R,Jiang T,et al.Circadian Blood Pressure Rhythm in Cardiovascular and Renal Health and Disease[J].Biomolecules,2021,11(6):868.[10]何善娴,王以新,王雷,等.不同用药时间对原发性高血压患者晨峰血压的影响[J].中国医药,2018,13(9):1288-1292.[11]卓练强,叶柳青,熊方.替米沙坦不同给药时间对轻中度原发性高血压病患者动态血压监测参数及超敏C反应蛋白水平的影响[J].中国医院用药评价与分析,2019,19(3):312-314.[12]余国栋.高血压患者用替米沙坦治疗期间不同给药时间对疗效的影响[J].中国继续医学教育,2019,11(2):127-129.[13]周海.高血压患者应用替米沙坦不同给药时间治疗的效果分析[J].心血管病防治知识(学术版),2019,9(11):6-7.[14]闫小滨,赵冬太,王耀峰.替米沙坦不同服药时间治疗非杓型伴清晨高血压[J].牡丹江医学院学报,2020,41(3):111-113.[15]刘广旭,马海英.替米沙坦治疗高血压的疗效与用药时间的关系[J].现代医学,2017,45(7):984-986.[16]李益.替米沙坦不同给药时间用于高血压治疗的疗效分析[J].心血管病防治知识(学术版),2017,18(12):17-18.[17]王靖,王晋生,李娜,齐云霞,闫蕊.伴有高血压的维持性血液透析患者透析期间血压节律变化特点及干预研究[J].河北医科大学学报,2018,39(5):528-532.[18]方子美,周明敏.心率变异性的降低对难治性高血压患者夜间血压下降幅度减弱的影响[J].中国循证心血管医学杂志,2020,12(3):356-360.[19]张小平,邓艳.替米沙坦不同给药时间治疗非杓型高血压的临床分析[J].湖北科技学院学报(医学版),2016,30(1):17-19.[20]程海涛,胡文辉.急性脑梗死患者颈动脉粥样硬化斑块与血hs-CRP、FIB及HCY的关系[J].内科急危重症杂志,2018,24(4):306-308.

相似文献/References:

[1]颜 明,龚丽娜,王淑清.彩超在高血压患者肾动脉血流动力学检测中的应用分析[J].医学信息,2018,31(02):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
 YAN Ming,GONG Li-na,WANG Shu-qing.Application of Color Doppler Ultrasound in the Measurement of Renal Artery Hemodynamics in Patients with Hypertension[J].Medical Information,2018,31(14):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
[2]夏能能,任 薇,杜建平,等.1953~2016年中医药治疗高血压领域研究热点分析[J].医学信息,2018,31(04):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
 XIA Neng-neng,REN Wei,DU Jian-ping,et al.Analysis of Hot Spots in the Research of Traditional Chinese Medicine in Treating Hypertension from 1953 to 2016[J].Medical Information,2018,31(14):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(14):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
 QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Medical Information,2018,31(14):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[5]董巧玲.健康教育对原发性高血压患者治疗效果的影响[J].医学信息,2018,31(09):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
 DONG Qiao-ling.Effect of Health Education on Treatment of Patients with Essential Hypertension[J].Medical Information,2018,31(14):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
[6]汤海霞,班 涛.大黄素与心血管疾病的研究[J].医学信息,2022,35(11):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
 TANG Hai-xia,BAN Tao.Research on Emodin and Cardiovascular Diseases[J].Medical Information,2022,35(14):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
[7]沈 正,王庆海.焦虑抑郁障碍与血压变异性研究[J].医学信息,2018,31(16):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
 SHEN Zheng,WANG Qing-hai.Study on Anxiety and Depression Disorder and Blood Pressure Variability[J].Medical Information,2018,31(14):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
[8]左洪亮.苯磺酸左旋氨氯地平片治疗中老年患者 轻中度原发性高血压的疗效观察[J].医学信息,2018,31(16):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
 ZUO Hong-liang.Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients[J].Medical Information,2018,31(14):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
[9]袁 敏,周袁成.钙离子拮抗剂类降压药的临床应用与不良反应分析[J].医学信息,2018,31(17):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
 YUAN Min,ZHOU Yuan-cheng.Clinical Application and Adverse Reaction Analysis of Calcium Antagonist Antihypertensive Drugs[J].Medical Information,2018,31(14):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
[10]陈学军,李 敏,张 丹,等.社区一体化分级管理模式对社区老年高血压患者的管理效果[J].医学信息,2018,31(18):169.[doi:10.3969/j.issn.1006-1959.2018.18.055]
 CHEN Xue-jun,LI Min,ZHANG Dan,et al.Management Effect of Community Integration Hierarchical Management Mode on Elderly Hypertensive Patients in Community[J].Medical Information,2018,31(14):169.[doi:10.3969/j.issn.1006-1959.2018.18.055]
[11]宋晨音.苯磺酸氨氯地平联合替米沙坦治疗高血压病的有效性和安全性研究[J].医学信息,2022,35(02):166.[doi:10.3969/j.issn.1006-1959.2022.02.043]
 SONG Chen-yin.Study on Efficacy and Safety of Amlodipine Besylate Combined with Telmisartanin the Treatment of Hypertension[J].Medical Information,2022,35(14):166.[doi:10.3969/j.issn.1006-1959.2022.02.043]

更新日期/Last Update: 1900-01-01